rac-(1R,2S,4R,5R)-5-aminobicyclo[2.2.1]heptan | 911718-30-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: rac-(1R,2S,4R,5R)-5-aminobicyclo[2.2.1]heptan
• 英文别名: (1R,2R,4R)-Bicyclo[2.2.1]heptan-2-amine
• CAS: 911718-30-4
• 化学式: C₇H₁₃N
• 分子量: 111.187
• InChiKey: JEPPYVOSGKWVSJ-FSDSQADBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  rac-(1R,2S,4R,5R)-5-aminobicyclo[2.2.1]heptan 以43%的产率得到
  参考文献：
  名称：

  LARSEN, SCOTT D.;SPILMAN, CHARLES H.;BELL, FRANK P.;DINH, DAC M.;MARTINBO+, J. MED. CHEM., 34,(1991) N, C. 1721-1727

  摘要：

  DOI：

文献信息

• [EN] IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES<br/>[FR] IMIDAZOPYRROLOPYRIDINE EN TANT QU'INHIBITEURS DE LA FAMILLE JAK DE KINASES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018112382A1

  公开（公告）日：2018-06-21

  2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.

  2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile化合物，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗由JAK介导的疾病状态、紊乱和疾病，如炎症性肠病的方法。
• Diarylsulfone sulfonamides and use thereof
  申请人：Gopalsamy Ariamala

  公开号：US20060276464A1

  公开（公告）日：2006-12-07

  Compounds of Formula 1, or pharmaceutically acceptable salts thereof, are provided: which are modulators of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat a variety of disorders, including osteoporosis.

  提供公式1的化合物或其药用可接受盐：它们是分泌的毛细胞突变相关蛋白-1的调节剂。这些化合物和含有这些化合物的组合物可用于治疗多种疾病，包括骨质疏松症。
• Prophylactic/Therapeutic Agent for Diabetes
  申请人：Cho Nobuo

  公开号：US20090264650A1

  公开（公告）日：2009-10-22

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种11β-羟基类固醇脱氢酶1抑制剂，其包括由式（1）表示的化合物，其中每个符号如描述中所定义的，或其盐或前药。本发明的11β-羟基类固醇脱氢酶1抑制剂具有优异的活性，可用作药物剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖症、异常脂质代谢、高血压等的药剂。
• Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors
  申请人：ALLEN David George

  公开号：US20080175914A1

  公开（公告）日：2008-07-24

  The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl, —CH 2 CH 2 OH or —CH 2 CH 2 CO 2 C 1-2 alkyl; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3 is optionally substituted C 3-8 cycloalkyl or optionally substituted mono-unsaturated-C 5-7 cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n 1 and n 2 independently are 1 or 2; and in which Y is O, S, SO 2 , or NR 10 ; or R 3 is a bicyclic group (dd) or (ee): and wherein X is NR 4 R 5 or OR 5a . The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE 4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

  本发明涉及公式（I）的化合物或其盐： 其中： R1是C1-4烷基，C1-3氟烷基，-CH2CH2OH或-CH2CH2CO2C1-2烷基; R2是氢原子（H），甲基或C1氟烷基; R3是可选取代的C3-8环烷基或可选取代的单不饱和C5-7环烯基或亚公式（aa），（bb）或（cc）的可选取代的杂环基; 其中n1和n2独立地为1或2; Y是O，S，SO2或NR10; 或R3是双环基（dd）或（ee）： 其中X是NR4R5或OR5a。 该化合物是磷酸二酯酶（PDE）抑制剂，特别是PDE4抑制剂。本发明还提供了公式（I）的化合物或其药学上可接受的盐的用途，用于制造治疗和/或预防哺乳动物，如人类的炎症性和/或过敏性疾病的药物，例如慢性阻塞性肺疾病（COPD），哮喘或过敏性鼻炎。
• PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1864971A1

  公开（公告）日：2007-12-12

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种 11β-羟基类固醇脱氢酶 1 抑制剂，由式（1）代表的化合物组成： 其中各符号如说明中所定义，或其盐，或其原药。本发明的11β-羟类固醇脱氢酶1抑制剂具有优异的活性，可作为药物制剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖、脂代谢异常、高血压等疾病的药物。